Specialist and experienced pricing and market access consultancy
We will develop and implement a successful launch strategy for your product.
We build payer focussed pricing and market access strategies to enable commercial success.
We provide engaging training solutions that ensures your organisation stays ahead of the ever-changing market access landscape.
Unifying our internal strengths and external partnerships helps solve your pricing and market access challenges to drive patient access of your pharmaceutical products.
Clearly and concisely communicate key scientific, economic and commercial messages to enable company employees to effectively communicate the product’s value.
Individual solutions to suit you
We adapt our working style to reflect your needs
We have a wealth of practical knowledge & experience within the pharma industry & HTA bodies
We react quickly and effectively to provide the best support possible
Given the overlap in Joint Clinical Assessment (JCA) and national-level HTA timelines, manufacturers…
Read morePredicting PICO requirements can help pharmaceutical manufacturers anticipate the populations, compa…
Read moreIntroduction The EU Joint Clinical Assessment (JCA) was introduced to reduce duplication and establi…
Read moreJoint Clinical Assessment (JCA) provides a common EU-level clinical assessment, but national HTA and…
Read moreIntroduction Announced in the 2025 NHS 10-year plan, the National HealthTech Access Programme (NHAP)…
Read moreIntroduction Understanding differences in HTA outcomes across markets remains challenging due to var…
Read moreIntroduction Digital twins are dynamic digital representations that combine patient-specific multidi…
Read moreIntroduction European public healthcare systems are facing increasing budget pressure, driven by pos…
Read more